Traversing the Ethical, Legal, and Societal Dimensions of Pediatric Biobanking with Biospecimen Tracking and Management Software

Biospecimen Tracking and Management Software for Pediatric Biobanking

The utilization of biological materials and data obtained from children for research purposes has ignited fervent debates within the global ethical community, with the fulcrum of these discussions being how pediatric biobanking is not merely about storing samples; it’s about safeguarding the well-being of our most vulnerable population while advancing the frontiers of science. 

This comprehensive blog explores the ethical, legal, and societal dimensions surrounding the collection and preservation of biological samples from children. From grappling with the ethical complexities of informed consent to navigating the legal landscape of minors’ capacity to participate in research, it elucidates the multifaceted challenges in pediatric biobanking.

Understanding Pediatric Biobanking and the Concept of Vulnerability

At its core, pediatric biobanking involves the collection and preservation of biological samples—ranging from blood and tissue to genetic data—from children to advance scientific knowledge and medical treatments. It is driven by the recognition of children as a vulnerable population, inherently deserving special care and protection, as articulated in Article 25(2) of the Universal Declaration of Human Rights. Children, in their developmental journey, lack the legal capacity to provide informed consent and are thus reliant on guardians or legal representatives to safeguard their interests. Consequently, pediatric biobanking operates within a framework that acknowledges the unique vulnerabilities of children and seeks to mitigate potential risks while harnessing the immense potential for medical breakthroughs.

Ethical Issues in Pediatric Biobanking

At the heart of ethical considerations in pediatric biobanking is “informed consent,” which presents unique challenges in the context of children’s participation. While legal guardians are typically responsible for providing consent on behalf of minors, the notion of assent has emerged to involve children in the decision-making process to the extent of their maturity. However, reconciling the ethical imperative to respect children’s evolving autonomy with the legal requirements for consent remains a contentious issue within the ethical community. 

Ethical practice in pediatric biobanking entails careful consideration of the risks and benefits associated with participation. However, the assessment of potential risks against potential benefits is challenging. Firstly, clinical trial regulations emphasize the need to balance benefits and risks. However, in the context of pediatric biobank research, the direct benefits to participants are often minimal or absent, as the research is primarily non-therapeutic and aimed at generating potential benefits for future patients and broader scientific advancements. Furthermore, pediatric research typically involves minimal physical risk, as interventional procedures are limited to sample collection moments. Assessing risks against potential benefits becomes complex when the risks are not primarily physical and the immediate benefits to participants are minimal.

Next, the risks associated with pediatric biobanking extend beyond physical and emotional harm to include significant privacy concerns, especially concerning genetic information and data processing. The transmission of personal data nationally and transnationally poses heightened risks for children. Of particular concern is the informational risk, particularly evident in genetic profiling, where once the biological sample is exhausted, the associated researcher-generated data remains accessible and reproducible, potentially disseminating widely within the scientific community. Consequently, when minors reach adulthood and are approached for consent regarding their stored samples, their identifying DNA sequences and associated data may already have been distributed globally. 

Moreover, the use of Artificial Intelligence (AI) and Machine Learning (ML), may inadvertently perpetuate discrimination and stigma, posing significant ethical and social risks to participants. These technologies may lead to group-based generalizations and inferences, which could result in harmful stereotyping and discrimination against certain groups. This can have repercussions not only in terms of health outcomes but also in terms of social harm. Child participants and their families may be adversely affected. Individuals who unexpectedly find themselves categorized into specific groups by these new technologies could experience negative consequences. These uncertain future scenarios pose significant challenges for Institutional Review Boards (IRBs) and Research Ethics Committees (RECs).

Legal Dimensions in Pediatric Biobanking

Pediatric biobanking presents a unique set of legal challenges, primarily revolving around the complex issue of informed consent and the varying capacities of minors to understand the implications of their participation.

The ability of minors to participate in research is governed by the age of legal majority, which differs across jurisdictions. This variation poses challenges for harmonizing biobank policies across countries, where age limits for consent to treatment and research vary widely. From fixed age thresholds to assessments of capacity based on maturity, the approaches differ significantly, reflecting the absence of a unified legal framework.

Central to the ethical conduct of pediatric research is the concept of assent. While legally competent consent is obtained from parents or legal guardians, assent serves as an ethical requirement for minors deemed legally incompetent. However, the requirement for assent is not universally recognized, with some jurisdictions using alternative terms like “agreement.” This inconsistency underscores the need for clarity and standardization in legal requirements for involving minors in research.

Determining the age at which minors can provide meaningful assent poses further challenges. IRBs grapple with assessing minors’ capacity to understand the risks and benefits of research participation. Suggestions for acceptable ages range from 7 years to adolescence, with considerations of cognitive development and maturity influencing the decision-making process. 

Cognitive development plays a crucial role in determining minors’ capacity to provide informed assent. Guidelines emphasize the importance of understanding, appreciating, and communicating voluntary choices. However, the lack of consensus on standardized assessment methods and parameters complicates the process of evaluating minors’ decision-making capacities.

Societal Issues in Pediatric Biobanking

The lack of awareness and engagement in pediatric biobanking poses a significant societal issue, hindering the progress of pediatric research. While informed consent from parents and assent from minors are crucial, many parents are unaware of the role of biobanking and research, leading to missed opportunities for participation.

Efforts to disseminate information through dedicated websites and educational programs in schools are crucial in addressing this gap. Successful initiatives, such as the “Open doors in biobanks” program of the Italian National Node, which provides hands-on experience at a biobank for high school students, foster greater awareness and engagement. Tailored tools and activities, such as visits to biobanks and digital media, can effectively engage children of different age groups.

Best Practices in Pediatric Biobanking

Adherence to best practices and ethical guidelines ensures the responsible and equitable conduct of research. Central to these best practices is the commitment to upholding ethical and legal compliance throughout all stages of the biobanking process. This includes robust consent management procedures that prioritize the autonomy and well-being of pediatric participants, as well as clear governance structures that promote transparency and accountability. Furthermore, strategies for the responsible use of biological samples and data are imperative, including measures to mitigate privacy risks, safeguard participant confidentiality, and minimize the potential for harm. 

Establishing effective communication and engagement with child participants is paramount to ensure their understanding of the research process, including its benefits and risks. Practical suggestions for enhancing engagement include prioritizing the provision of practical information related to sample collection and gradually introducing more abstract concepts as children’s capacities develop. Utilizing diverse communication methods, including verbal, written, and digital means, enhances accessibility and comprehension. Investment in training competent staff to interact with minors and obtain their assent is essential to ensure ethical practice and minimize coercion. Recognizing that legal consent requires the authorization of parents or guardians underscores the importance of effective communication not only with children but also with their families. 

The Role of Biospecimen Tracking and Management Software in Pediatric Biobanking

Biospecimen tracking and management software, also known as laboratory information management system (LIMS), can play an important role in ensuring ethical, legal, and societal compliance while facilitating efficient management of biological samples and associated data. A biobanking LIMS enables transparent and accountable handling of sensitive information, safeguarding participant confidentiality and privacy, and promoting clear governance structures that enhance transparency and accountability. The sensitive information may include phenotypic and genomic data of participants. Moreover, a LIMS enables efficient sample tracking and traceability, reducing the risk of errors and ensuring the integrity of data. A LIMS enables biobankers to securely store consent documentation and track the latest consent/assent status, ensuring that all necessary permissions are obtained before samples are collected and stored. This includes recording detailed information about the consent obtained from parents or legal guardians, as well as any assent provided by the pediatric donors themselves, in cases where they are deemed capable of understanding the research implications. Furthermore, a LIMS helps in managing the training of staff members who interact with minors and obtain their assent.


Pediatric biobanking is a tricky balancing act between safeguarding the interest of children and moving science forward. It’s like walking a tightrope. Doing this right demands navigating ethical, legal, and societal considerations with diligence. By adhering to ethical best practices, respecting legal frameworks, and championing community engagement, we can ensure that pediatric biobanking not only adheres to the highest standards of integrity but also aligns with the values of compassion and respect for children’s rights. Biobanks can leverage biospecimen tracking and management software to overcome the challenges of pediatric biobanking. Biospecimen tracking and management software can streamline data management, manage and track consent, and help biobanks uphold the highest standards of integrity and privacy protection.

Leave a Reply

Your email address will not be published. Required fields are marked *